Reports Q3 revenue $12.5M, consensus $4.64M. “We are very pleased with the first weeks of the VIZZ launch as we introduce our exciting new solution for the treatment of presbyopia into the marketplace and have been highly encouraged by the enthusiasm from the ECP community, as evidenced by the over 2,500 unique prescribers and impressively over 5,000 prescriptions filled through October. Early patient feedback has been very positive, and it is undisputed that VIZZ is highly effective at restoring near vision with rapid onset and long duration,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics (LENZ). “The months ahead promise to continue to be very exciting, and we are proud to announce today our partnership with Sarah Jessica Parker as campaign spokesperson to lead the VIZZ DTC campaign which we intend to launch in Q1 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Positive Outlook on LENZ Therapeutics’ VIZZ Eye Drop Launch Drives Buy Rating
- Short Report: Bears pare exposure to Beyond Meat, add to Krispy Kreme
- Lenz Therapeutics price target raised to $67 from $51 at Piper Sandler
- LENZ Therapeutics Raises $80M Through Stock Sale
- Short Report: TeraWulf short interest at record high despite stock strength